SO
CTMX icon

STRS Ohio’s CytomX Therapeutics CTMX Stock Holding History

STRS Ohio’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-106,900
Closed -$285K – 2092
2022
Q1 		$285K Hold
106,900
– – ﹤0.01% 1613
2021
Q4 		$462K Hold
106,900
– – ﹤0.01% 1505
2021
Q3 		$544K Sell
106,900
-8,900
-8% -$47.6K ﹤0.01% 1477
2021
Q2 		$733K Buy
115,800
+26,900
+30% +$209K ﹤0.01% 1409
2021
Q1 		$687K Hold
88,900
– – ﹤0.01% 1431
2020
Q4 		$582K Buy
88,900
+11,700
+15% +$83.6K ﹤0.01% 1387
2020
Q3 		$513K Buy
77,200
+21,100
+38% +$156K ﹤0.01% 1315
2020
Q2 		$467K Buy
56,100
+4,600
+9% +$42.7K ﹤0.01% 1354
2020
Q1 		$395K Hold
51,500
– – ﹤0.01% 1311
2019
Q4 		$427K Sell
51,500
-8,400
-14% -$56.7K ﹤0.01% 1499
2019
Q3 		$442K Hold
59,900
– – ﹤0.01% 1349
2019
Q2 		$672K Buy
59,900
+4,200
+8% +$44K ﹤0.01% 1043
2019
Q1 		$598K Buy
55,700
+17,800
+47% +$263K ﹤0.01% 1152
2018
Q4 		$572K Hold
37,900
– – ﹤0.01% 1126
2018
Q3 		$701K Hold
37,900
– – ﹤0.01% 1156
2018
Q2 		$866K Buy
37,900
+10,800
+40% +$276K ﹤0.01% 992
2018
Q1 		$770K Sell
27,100
-9,400
-26% -$268K ﹤0.01% 1041
2017
Q4 		$770K Sell
36,500
-4,100
-10% -$85K ﹤0.01% 1032
2017
Q3 		$737K Sell
40,600
-7,000
-15% -$109K ﹤0.01% 1108
2017
Q2 		$737K Buy
47,600
+35,600
+297% +$537K ﹤0.01% 1039
2017
Q1 		$207K Buy
+12,000
New +$158K ﹤0.01% 1529
2016
Q4 		– Sell
-2,400
Closed -$37K – 1936
2016
Q3 		$37K Sell
2,400
-100
-4% -$1.21K ﹤0.01% 1800
2016
Q2 		$25K Hold
2,500
– – ﹤0.01% 1850
2016
Q1 		$32K Hold
2,500
– – ﹤0.01% 1801
2015
Q4 		$52K Buy
+2,500
New +$39.6K ﹤0.01% 1788

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

STRS Ohio's CTMX Position: Q2 2022 in Review

STRS Ohio sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 106,900 shares — an estimated $285K sold.

STRS Ohio first reported a position in CTMX in Q4 2015 and held it in 25 quarters. The position peaked at $866K in Q2 2018. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • STRS Ohio reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • STRS Ohio sold 106,900 CytomX Therapeutics shares in Q2 2022, an estimated $285K.
  • STRS Ohio first reported a position in CytomX Therapeutics in Q4 2015 and held it in 25 quarters.
  • STRS Ohio's CytomX Therapeutics position peaked at $866K in Q2 2018.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.